Abstract
Deuterated (“heavy”) water labeling in patients with chronic lymphocytic leukemia (CLL) demonstrates that IGHV unmutated and ZAP-70+ patients have higher blood and tissue CLL death rates on ibrutinib therapy, resulting in lower measurable residual disease levels with long-term ibrutinib treatment. This trial was registered at www.clinicaltrials.gov as #NCT01752426.
Original language | English (US) |
---|---|
Pages (from-to) | 2678-2681 |
Number of pages | 4 |
Journal | Blood |
Volume | 144 |
Issue number | 25 |
DOIs | |
State | Published - Dec 19 2024 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology